期刊
PHARMACOLOGY & THERAPEUTICS
卷 119, 期 3, 页码 326-339出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pharmthera.2008.06.001
关键词
late Na+ current; long QT syndromes; cardiac arrhythmias; myocardial remodeling; myocardial ischemia; Na+ channel blockers
The late sodium current (I-NaL) is a sustained component of the fast Na+ current of cardiac myocytes and neurons. As recently appreciated, common neurological and cardiac conditions are associated with abnormal I-NaL enhancement, which may contribute to the pathogenesis of both electrical and contractile dysfunction. For this reason, I-NaL has become an appealing pharmacological target, with a potentially broad range of therapeutic indications. The recent approval by the FDA of an I-NaL blocker (ranolazine) for clinical use justifies the increased interest in I-NaL as a pathogenic mechanism and the rapid evolution of the information concerning it. The review focuses on cardiac aspects of I-NaL enhancement; it deals with the origin of I-NaL, with its pathophysiological role and with the consequences of its pharmacological modulation. Both basic aspects and clinical evidence are discussed. (C) 2008 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据